This page is updated frequently with new Peptide-related patent applications.
| List of recent Peptide-related patents
|Computer-implemented associations of nucleic and amino acid sequence polymorphisms with phenotypes.|
Computer-implemented methods that associate one-hundred percent of the nucleic or amino acid sequence polymorphisms of a particular length with an examined phenotype. Each association is documented by the number of case and control group individuals on whose sequences the polymorphism occurs, as well as relative risk, chi square, and correlation statistics.
|Solid phase extraction of global peptides, glycopeptides, and glycans using chemical immobilization in a pipette tip|
Pipette tips comprising aldehyde-reactive or amino-reactive chemical moieties or other chemical moieties capable of conjugating to one or more reactive groups of amino acid side chains or protein modifications and methods for preparing the tips are provided. In addition, a high throughput method for identifying proteins, glycoproteins, and glycans in a plurality of samples using the pipette tips is also provided..
The Johns Hopkins University
|High-throughput single molecule protein identification|
The present invention is methods and assays for identifying single proteins from a sample, without the use of affinity reagents. The methods and assays combine endopeptidase-based component of conventional peptide mapping with single molecule labeling and a microreactor array platform.
The Trustees Of Columbia University In The City Of New York
|Non-ribosomal protein synthesis pigment fusion peptides|
The present invention relates to a polypeptide or polypeptide complex, comprising at least one non-ribosomal peptide synthesis (nrps) amino acid module functionally connected to at least one pigment module. The present invention further relates to a labeled oligopeptide comprising a non-naturally attached nrps pigment or/and polyketide pigment, to a polynucleotide encoding a fusion polypeptide, a vector, preferably an expression vector, comprising the polynucleotide of the present invention and to a host cell comprising the polypeptide or polypeptide complex and/or the polynucleotide, and/or the vector according to the present invention.
|Biopolymer-mediated assembly of nanoparticles using genetically encoded proteins|
Various aspects and embodiments provided herein are directed to compositions that include at least one nanoparticle linked to a first polypeptide, and a biologically synthesizable polymer linked to at least one second polypeptide that binds covalently to the first polypeptide. Other aspects and embodiments provided herein are directed to methods of producing the foregoing compositions and components therein..
Massachusetts Institute Of Technology
|Method of semi-solid state fermentation for producing surfactin from a mutant strain of bacillus subtilis subsp|
Surfactin is produced from bacillus subtilis ssp. Containing sfp gene (lipopeptide biosurfactants produced by fermentation).
Saft Biotechnology Com. Ltd
|High molecular weight pha-producing microbe and producing high molecular weight pha using same|
An object of the present invention is to provide a microorganism strain that accumulates a high molecular weight pha, and a pha production method using the microorganism. The present invention provides a method for producing a pha copolymer, which includes culturing a microorganism, wherein at least a portion of either of the following genes (a) and (b) of the microorganism has been altered by substitution, deletion, insertion, and/or addition to reduce or eliminate the activity of a pha degrading enzyme encoded by the gene: (a) a pha degrading enzyme gene encoding the amino acid sequence of seq id no:2 in the sequence listing; and (b) a gene encoding a polypeptide having at least 85% sequence identity to the amino acid sequence of seq id no:2 in the sequence listing and having pha degrading enzyme activity..
|Peptide oligonucleotide conjugates|
Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mrna splice products produces beneficial therapeutic effects..
Sarepta Therapeutics, Inc.
|Human trypsinogen with reduced autoactivation and its use in an immunoassay|
The present invention relates to a polypeptide consisting of or comprising a variant of human trypsinogen-1, comprising the substitutions: amino acid residue e64 is replaced with an amino acid residue comprising a positively charged side chain, amino acid residue k123 is replaced with an amino acid residue comprising an aliphatic side chain and amino acid residues y139 and d147 are replaced with a glutamine or asparagine residue, and wherein said variant is further characterized in that: an amino acid residue selected from e16, e17 and e142 is replaced with an amino acid residue comprising an aliphatic side chain, and/or amino acid residue n18 is replaced with a histidine residue, and/or amino acid residue r107 is replaced with a lysine residue, and/or amino acid residue d138 is replaced with an amino acid residue comprising a positively charged side chain, and wherein said variant is cleavable into a polypeptide having a native-like enzymatic activity when compared to human trypsin-1.. .
|Polypeptides having xylanase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Lysosomal protein targeting sequence and therapeutic applications of same
The present disclosure relates to methods of treating diseases states such as lysosomal storage diseases and/or neurodegenerative diseases. Also disclosed are one or more compositions that may be useful for one or more of the disclosed methods, including compositions that may comprise acid β-glucosidase (gcase) protein comprising one or more mutations, peptides of acid β-glucosidase, and dna vectors and cell lines related to acid β-glucosidase peptides or proteins..
Children's Hospital Medical Center
Method of using biosurfactants as acid corrosion inhibitors in well treatment operations
Corrosive effects arising during well treatment applications are inhibited and/or prevented by introducing into the well composition containing a corrosion inhibitor of a biosurfactant selected from glycolipids (other than sophorolipids and mannosylerythritol lipids), phospholipids; polyol lipids; lipoproteins, lipopeptides, ornithine lipids, carbohydrate-lipids, neutral lipids, aminoacid lipids, exolipids, liposan; siderolipids, protein polyamines diglycosyl diglycerides, fimbriae, saponified triglycerides and fatty acids. The composition may also contain a corrosion inhibitor intensifier..
Baker Hughes Incorporated
Thermoset rubber reinforced by supramolecule building blocks
A thermoset rubber composition includes a thermoset rubber having crystalized domains dispersed therein, the crystalized domains being formed of supramolecule building blocks forming a plurality of sheet-like structures through hydrogen bonding, the sheet-like structures interacting through non-covalent interactions to form the crystalized domains within the thermoset rubber. The supramolecular building blocks may be peptides, β-peptides, aramid oligomers, and bis-ureas..
Rubber composition and pneumatic tire
The present invention is directed to a rubber composition comprising a diene based elastomer comprising a functional group selected from the group consisting of hydroxyl, primary amine, and secondary amine; and a binding agent selected from the group consisting of water-dispersible resin, polyelectrolytes, and polypeptides. The invention is further directed to a pneumatic tire including the rubber composition, and a method of increasing the green strength in a rubber composition..
The Goodyear Tire & Rubber Company
Methods for post-fabrication functionalization of poly(ester ureas)
Amino acid-based poly(ester urea)s (peu) are emerging as a class of polymers that have shown promise in regenerative medicine applications. Embodiments of the invention relate to the synthesis of peus carrying pendent “clickable” groups on modified tyrosine amino acids.
The University Of Akron
Antibody therapeutics that bind ctla4
There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.
Cation and anion exchange chromatography method
Herein is reported a method for purifying a polypeptide comprising the steps of i) applying a solution comprising the polypeptide to an ion exchange chromatography material, and ii) recovering the polypeptide with a solution comprising a denaturant and thereby purifying the polypeptide, whereby the ion exchange chromatography material comprises a matrix of cross-linked poly (styrene-divinylbenzene) to which ionic ligands have been attached, and wherein the solution comprising the polypeptide applied to the ion exchange chromatography material is free of the denaturant and the polypeptide adsorbed to the ion exchange chromatography material is recovered with a solution comprising a denaturant at a constant conductivity.. .
Hoffmann-la Roche Inc.
Polypeptides and methods for modulating d1-d2 dopamine receptor interaction and function
The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal d1-d2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from d1-d2 coupling and/or activation.
Centre For Addiction And Mental Health
Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
The present disclosure provides chimeric proteins having an n-terminus coupled to a c-terminus, wherein the n-terminus comprises an n-terminal portion of fibroblast growth factor (fgf) 2 and the c-terminus comprises a portion of an fgf1 protein. Such fgf2/fgf1 chimeras can further include a fibroblast growth factor receptor (fgfr) 1c-binding protein, a β-klotho-binding protein, or both.
Salk Institute For Biological Studies
Fusion polypeptides comprising mucin-domain polypeptide linkers
The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans..
Apelin fusion proteins and uses thereof
The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an fc domain, a fragment of an fc domain, or a variant of an fc domain.
Regeneron Pharmaceuticals, Inc.
Mitochondrial targeting and therapeutic use thereof
The present invention provides, among other things, compositions and methods for treatment of friedrich's ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural fxn protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an n-terminus and a c-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the n-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the c-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry..
Shire Human Genetic Therapies, Inc.
Recombinant peptide vaccines against ticks, and nucleotide sequences coding for the recombinant peptides
The present invention relates to the field of biotechnology and genetic engineering, and particularly to the expression of recombinant peptides. The inoculation thereof in cattle results in the production of an immune response capable of adversely affecting rhipicephalus microplus ticks, which feed on the inoculated cattle, decreasing the number and reproductive capacity of this tick species.
Patsos Endustria E Comercio De Produtos BiotecnolÓgicos Ltda
Compositions and methods for the treatment of viral infections
The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as sah). The compositions are useful for treating and/or preventing viral infections.
Dana-farber Cancer Institute, Inc.
Compounds that bind to human immunodeficiency virus rev response element
Disclosed herein are compounds (such as peptides or peptide mimetics) that bind to hiv rre rna. In some examples, the compounds inhibit (for example, decrease) binding of rev to the rre rna.
The United States Of America, As Represented By Th E Secretary, Dept. Of Health And Human Services
Polyomavirus peptide sequences
The current invention concerns the identification of b-cell epitopes (as linear peptides) from human polyoma virus proteins and their use in an immune diagnostic assay.. .
Janssen Diagnostics Bvba
C-met protein agonist
Object of the present invention is to provide a peptide functioning as a c-met agonist. The present invention provides a peptide complex comprising two or more peptides that bind to a c-met protein and a linker that links the two or more peptides to one another.
The University Of Tokyo
Leukemia stem cell targeting ligands and methods of use
The present invention is directed to c-type lectin-like molecule-1 (cll1) specific ligand peptides, comprising the amino acid motif lr(s/t), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (lscs) and targeted therapy against leukemia mediated at least in part by cll1-expressing lscs.. .
The Regents Of The University Of California
Connective tissue stimulating peptides
Novel peptides are described which comprise an amino acid motif selected from the group consisting of “pg”, “gp”, “pi” and “ig” and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein “p” in the motif is proline or hydroxyproline and the peptide stimulates the development, maintenance and repair of bone, cartilage and associated connective tissue. The invention further relates to pharmaceutical compositions of these peptides, as well as therapeutic and prophylactic uses of such peptides..
Site-specific chemoenzymatic protein modifications
The present invention relates to methods and reagents for use in site-selective modification of proteins having lysine residues with functionalized peptides using a chemoenzymatic microbial transglutaminase-mediated reaction. The functionalized proteins may be used for study or therapeutic uses..
Purification of organic compounds by surfactant mediated preparative hplc
A sample is provided that can be purified by preparative reversed phase high performance liquid chromatography (prep-rp-hplc) in a single run in spite of recent advances in the production of reversed phase derivatized silica stationary supports: (1) the traditional approach is to use a bigger column (greater amount of stationary phase); and (2) use displacement chromatography which (while labor intensive to develop) uses the stationary phase more effectively. This disclosure describes a unique prep-rp-hplc technique that uses a c-18/c-8 derivatized silica coated with a surfactant such as triton x-100 to result in 7 to 10 fold increase in sample loading (of the crude mixture of organic compounds including synthetic crude peptides) in contrast to the conventional prep-rp-hplc technique.
Davuluri, Ramamohan Rao
Spect radionuclide-labeled trimeric cycle rgd peptide, preparation method thereof and imaging method thereof
The disclosure is related to a chemical structure, a preparation and an imaging method of a tumor imaging tracer, especially to a spect radionuclide-labeled trimeric cyclic rgd peptide: 99mtc-4p-rgd3, which functions as a ligand to be combined with integrin αvβ3 receptor in tumor for tumor imaging. The preparation includes linking hynic-osu with 4p-rgd3 to form hynic-4p-rgd3 and then chelating hynic with 99mtc to create 99mtc-4p-rgd3.
Bailing Cloud Biomedical Technologies Innovation
Vaults engineered for hydrophobic drug delivery
The invention relates to compositions of vault complexes for use as delivery agents for hydrophobic and/or aqueous insoluble therapeutic compounds. In one aspect, provided herein is a vault complex comprising a modified major vault protein (mvp), wherein the modified major vault protein comprises a fusion peptide, wherein said fusion peptide is fused to the n-terminus of the major vault protein, and wherein said peptide provides enhanced sequestering of a hydrophobic and/or aqueous insoluble therapeutic compound within the vault complex..
The Regents Of The University Of California
This document provides methods and materials related to treating cancer (e.g. Skin cancer).
Mayo Foundation For Medical Education And Research
Methods for dna-dependent targeting of a cell permeant antibody
The invention provides methods for selective targeting of live cells, which have undergone or are undergoing radiation or chemotherapy, at a site of interest with a cell-penetrating polypeptide. In one embodiment of the invention, the method comprises contacting the live cells with a cell-penetrating polypeptide comprising cell-penetrating determinants so that the cell-penetrating polypeptide binds extracellular dna near or around the live cells so as to form a complex or association therewith such that the complex or associated polypeptide-dna so bound bind the live cells and penetrates the live cells thereby selectively targeting live cells at a site of interest with a cell-penetrating polypeptide..
The United States Of America As Represented By The Department Of Veterans Affairs
Stable aqueous parenteral pharmaceutical compositions of insulinotropic peptides
Disclosed herein is an insulinotropic peptide multi-dose aqueous parenteral pharmaceutical composition and use thereof. A long-term storage formulation of the insulinotropic peptide can be obtained via the method of the present disclosure.
Shanghai Benemae Pharmaceutical Corporation
Methods of treating neuroendocrine tumors using frizzled-binding agents
Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a wnt antagonist.
Oncomed Pharmaceuticals, Inc.
Therapies, vaccines, and predictive methods for middle east respiratory syndrome virus (mers cov)
The present invention provides an isolated or synthesized protein fragment or peptide comprising at least one peptide sequence that is at least 50% homologous with at least one replikin peptide sequence identified in a mers cov. The at least one peptide sequence may be at least 80% homologous with at least one replikin peptide sequence identified in a mers cov.
Mosaic hiv envelope immunogenic polypeptides
Disclosed herein are mosaic hiv envelope (env) polypeptides that can elicit an immune response to hiv (such as cytotoxic t cell (ctl), helper t cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic env polypeptides, which include two or more (for example, three) of the polypeptides.
Dana-farber Cancer Institute
Chimeric ospa genes, proteins and methods of use thereof
The invention relates to the development of chimeric ospa molecules for use in a new lyme vaccine. More specifically, the chimeric ospa molecules comprise the proximal portion from one ospa serotype, together with the distal portion from another ospa serotype, while retaining antigenic properties of both of the parent polypeptides.
Brookhaven Science Associates, Llc
Vectors for expression of prostate-associated antigens
The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic paa polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.. .
Novel peptide having 4 linked ctl epitopes
This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for hla typing and regardless of the hla types of patients. Such peptide having 4 linked ctl epitopes is obtained by linking 4 ctl epitope peptides selected from among ctl epitope peptides derived from tumor antigen molecules that are reported to have the capacity for ctl induction via linkers..
Taiho Pharmaceutical Co., Ltd.
Novel peptide compound for inhibiting restenosis and promoting re-endothelialization and preparing the same
Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.. .
Chonnam National University Hospital
Cancer treatment method
Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (tpo) receptor agonist to such mammal, suitably a human.. .
Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
The present invention relates to novel amide derivatives of n-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor like-1 (fprl-1) receptor.. .
High-order sequence kernel methods for peptide analysis
System and methods are disclosed to perform peptide-mhc interaction prediction by applying a high-order kernel function to determine a similarity between peptide sequences; applying one or more supervised strategies to the kernel to encode relevant physicochemical and interaction information about peptide sequence and mhc molecule; and applying a classifier to the kernel to identify the peptide-mhc interaction of interest in response to a query.. .
Nec Laboratories America, Inc.
A analysing a sample immunoglobulin molecules
The inventions provides methods for analysing a sample of immunoglobulins, related peptides, and kits for carrying out such methods.. .
Methods of bh3 profiling
In various aspects the invention provides methods of predicting sensitivity of a cancer cell to a therapeutic agent by contacting a test cell population bh3 domain peptide; measuring the amount of bh3 domain peptide induced mitochondrial outer membrane permeabilization in the test cell population; and comparing the amount of bh3 domain peptide induced mitochondrial outer membrane permeabilization in the test cell population to a control cell population that has not been contacted with the therapeutic agent. An increase in mitochondrial membrane permeabilization in the test cell population compared to the control cell population indicates the cell is sensitive to the therapeutic agent..
Dana-farber Cancer Institute, Inc.
Methods and kits for determining predisposition to develop kidney diseases
Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one apol1 polypeptide variant which is characterized by a higher trypanolytic activity on trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type apol1 polypeptide as set forth in seq id no:1 on the trypanosoma brucei rhodesiense under identical assay conditions; or at least one apol1 nucleotide mutation in the aplo1 genomic sequence set forth in seq id no:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequlibrium (ld) with the s342g mutation in the apol1 polypeptide set forth in seq id no:1, wherein presence of the apol1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.. .
Ramot At Tel-aviv University Ltd.
Metabolically optimized cell culture
Improved methods for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, the method provides for culturing cells that have metabolically shifted.
Regeneron Pharmaceuticals, Inc.
Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
An improved nanoparticle for transfecting cells is provided. The nanoparticle includes a core polyplex and a silica coating on the core polyplex and, optionally, a polymer attached to an outer surface of the silica coating , where the polyplex includes an anionic polymer, a cationic polymer, a cationic polypeptide, and a polynucleotide.
Rensselaer Polytechnic Institute
Herbicide-resistant sunflower plants, polynucleotides encoding herbicide-resistant acetohydroxyacid synthase large subunit proteins, and methods of use
Herbicide-resistant sunflower plants, isolated polynucleotides that encode herbicide-resistant and wild-type acetohydroxyacid synthase large subunit (ahasl) polypeptides, and the amino acid sequences of these polypeptides, are described. Expression cassettes and transformation vectors comprising the polynucleotides of the invention, as well as plants and host cells transformed with the polynucleotides, are described.
Polypeptide regulating and controlling the formation of plant agronomic trait or yield trait, and use of polypeptide
The invention relates to a polypeptide for regulating agronomic characters and yield characters of plants and application thereof. The invention alters agronomic characters and yield characters of plants such as root development, tillering ability, heading period, panicle structure, grains number per panicle, grain morphology, and 1000 grains weight by directional regulating expression level of cytokinin-o-glycosyltransferase 1 in plants, thus achieve the aim of modifying plant type, panicle structure, grain morphology and weight, increasing yield..
Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences
E. coli separatome-based protein expression and purification platform
Provided is a separatome-based peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome of e. Coli.
Board Of Trustees Of The University Of Arkansas
Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
Isolated aspartyl-trna synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.. .
Atyr Pharma, Inc.
Purified lysin protein
The invention discloses a purified lysin protein for lysing acinetobacter baumannii cells without pretreatment process using chloroform or edta. The purified lysin protein includes a first peptide fragment and a second peptide fragment.
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Product and process for mucus viscosity normalization
Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin monocysteinic active site in a reduced state and optionally further contains a reducing system..
Orpro Therapeutics, Inc.
Protein-containing adhesives, and manufacture and use thereof
The invention provides protein adhesives and methods of making and using such adhesives. One type of protein adhesive described herein contains lignin and ground plant meal or an isolated polypeptide composition obtained from plant biomass.
Biopolymer Technologies, Ltd.